Study: Circadian’s anti-cancer therapy reduces tumour growth in animal models
 

Circadian Technologies Limited today released data demonstrating that its lead anti-cancer therapeutic, VGX-100, significantly inhibits tumour growth in a variety of different animal models (tumour xenografts) of human cancer.

More...